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The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was
treated successfully with a linezolid-containing regimen. It was found that linezolid is an
efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment
was maintained for 18 months, and closely monitoring toxicities did not reveal evidence of
any neurologic adverse effects. However, despite our expectation, thrombocytopenia was
seen after 2 years follow-up.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
An estimated 9 million people are infected with tuberculo-
sis (TB) worldwide [1]. In recent years, the epidemiology
of TB has shown significant increases in developed coun-
tries because of immigration from countries with high
prevalence as well as a rising incidence of TB and HIV
infection [2]. As a result, an increase of multidrug-resistant
(MDR)-TB is also anticipated over the next few years owing
to population migration patterns [3]. MDR-TB signifies
bacillary resistance to at least Isoniazid and Rifampicin
[4]. Drug-resistant TB infection has presented since the
beginning of the antibiotic era. Although genetic resistance-African Society for Myco
f Pulmonary, Critical Care
IL 60612-7323, USA. Tel.:
(M. Farshidpour), g_ebr@to an anti-TB medication happens naturally, in conse-
quence of chromosomal mutations that accompany myco-
bacterial replication, MDR-TB is a manmade phenomenon
that has emerged owing to improper TB treatment [5,6].
The management of MDR-TB is challenging, requiring pro-
longed administration of second-line drugs which are more
expensive, often less effective, and more toxic than
first-line agents [7,8].
Linezolid, the first oxazolidinone approved for clinical use,
has demonstrated excellent activity against drug-resistant
strains of Mycobacterium tuberculosis (MTB) [7,9,10].
The following report describes a case of MDR-TB that was
treated with a linezolid-containing regimen and discusses thebacteriology. Published by Elsevier Ltd. All rights reserved.
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adult with MDR-TB.
Case report
A29-year-old Bhutanese refugeemanwas referred to the clinic
for TB evaluation with positive tuberculin skin (PPD > 13 mm)
and QuantiFERON-TB tests. He was living in a camp in Nepal
for several years before moving to the United States. He com-
plained of cough, fever, and weight loss for 9 months. His past
medical history was not significant. The physical examination
was remarkable formalnourishment (bodymass index = 15.7),
mildly tender bilateral cervical lymphadenopathieswithmax-
imum size of 2 cm and decreased breath sounds in left lower
zone of the chest. The rest of the examination was normal.
Hematological and biochemical parameters were within nor-
mal limits except mild anemia.
Imaging studies were performed and showed a mild left
pleural effusion in the chest radiograph. A chest computed
tomography showed nodular opacities in the right upper lobe,
minimal scarring in the ligula, hilum lymph nodes with max-
imum size of 19 mm, and mild left side pleural effusion.
The sputum specimens were sent for the Acid Fast Bacilli
smear, mycological culture and drug susceptibility test
(DST). The patient underwent excisional biopsy of the cervical
lymph nodes, which the pathological examination reported
as chronic necrotizing granulomatosis inflammation consis-
tent with TB. Anti-TB therapy was started empirically with a
regimen including: isoniazid, rifampin, pyrazinamide, and
ethambutol on direct observe therapy. Eight weeks later, the
sputum and lymph node cultures reported mycobacterium
tuberculosis complex, and DST confirmed the presence of a
multiple drug-resistant strain, resistant to isoniazid, rifam-
pin, pyrazinamide, ethambutol, streptomycin and para
aminosalicylic sodium. The susceptibility results andmolecu-
lar study provided by the Center for Disease Control are
shown in Tables 1 and 2. The previous anti-TB regimen was
switched to amikacin 1500 mg/week, moxifloxacin 400 mg/Table 1 – Drug resistance results from sputum of MDR-TB patie
Drugs Percen
Isoniazid 0.2 lg/ml 100
Isoniazid 1.0 lg/ml 100
Isoniazid 5.0 lg/ml 0
Rifampin 1.0 lg/ml 100
Ethambutol 5.0 lg/ml 50
Streptomycin 2.0 lg/ml 100
Rifabutin 2.0 lg/ml 100
Ciprofloxacin 2.0 lg/ml 100
Kanamycin 5.0 lg/ml 0
Ethionamide 10.0 lg/ml 0
Capreomycin 10.0 lg/ml 0
PAS 2.0 lg/ml 50
Ofloxacin 2.0 lg/ml 0
Amikacin 4.0 lg/ml 0
Pyrazinamide 100 lg/ml 100
Susceptibility testing method: indirect agar proportion, 7H10 medium; su
develop on drug-free media. Pyrazinamide was tested by the MGIT 960 m
Abbreviations: R, resistance; S, sensitive; PAS, para-aminosalicylate sodiuday, cycloserine 500 mg/day, linezolid 600 mg/day and ethi-
onamide 500 mg/day. The patient responded well to anti-TB
medications, although he experienced multiple anti-TB med-
ication side effects, including thrombocytopenia, hearing loss
and upper gastrointestinal discomfort. Consequently, his
treatment was modified to linezolid 300 mg/day, cycloserine
500 mg/day, levofloxacin 750 mg/day and capreomycin
1300 mg/week (it was stopped 6 months after sputum conver-
sion due to hearing loss).
The anti-TB medicines were continued for 12 months after
sputum conversion to negative (total duration of treatment
was 18 months). The patient was free of symptoms and his
cervical lymphadenitis subsided. He was closely followed up
and no signs of relapse were observed up to 24 months after
completion of treatment. Thrombocytopenia (platelet counts:
86 · 1000 per microliter) was seen even 24 months after stop-
ping linezolid.
Discussion
Multidrug-resistant mycobacterium tuberculosis is a rising
and alarming medical problem. The actual management
and treatment regimens for MDR-TB are difficult, expensive,
long-term, and linked with high rates of adverse effects and
high morbidity and mortality [11,12]. Incomplete and inade-
quate treatment is the most significant factor leading to the
development of MDR-TB [13].
Linezolid is a synthetic antibacterial agent that inhibits
bacterial protein synthesis at an early stage of translation
[14]. The oral bioavailability of linezolid is nearly 100%, with
a high volume of distribution and high concentrations in alve-
olar macrophages [15]. Alternatively, various adverse drug
reactions have been describedwith long-term use of linezolid,
primarily bone marrow suppression and peripheral and/or
optic neuropathy. Hematologic adverse reactions ensuing
from the prolonged use of linezolid are dose dependent and
reversible secondary to inhibition of mitochondrial protein
synthesis, while peripheral neuropathy might be irreversiblent.
t resistance Interpretation
R
R
S
R
R
R
R
R
S
S
S
R
S
S
R
sceptibility is defined as <1% resistance compared with colonies that
ethod (Becton Dickinson).
m; lg/ml, microliter.
Table 2 – Results for molecular detection of drug resistance in MDR-TB patient.
Anti-TB drug Locus (region) examined Result for mutation
Rifampin rpoB-RRDR TCG > TTG; Ser531Leu
Isoniazid InhA (promoter) katG (ser315 codon) No mutation AGC > ACC; Ser315Thr
Fluoroquinolones gyrA (QRDR) No mutation
Amikacin, Kanamycin, and Capromycin rrs (1400 region) No mutation
Kanamycin eis (promoter) No mutation
Capromycin tlyA (entire ORF) No mutation
rpoB, rpoB gene encoding the b-subunit of RNA polymerase; RRDR, rifampin resistance-determining region; InhA, InhA gene encoding InhA
protein; katG, mycobacterial catalase-peroxidase; QRDR, quinolone resistance-determining regions; gyrA, DNA gyrase A gene; rrs, rrs gene of
the 16S rRNA; eis, eis gene; tlyA, tlyA gene; ORF, open reading frame.
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than dosage; however, optic neuropathy appears to resolve
after stopping linezolid [10,16]. In this case, treatment was
maintained for 18 months and closely monitoring toxicities
did not reveal evidence of any neurologic adverse effects.
However, despite previous reports, thrombocytopenia was
seen after 2 years of follow-up [17].
The optimal dose of linezolid for MDR-TB is not apparent.
In this case, linezolid was given at a dose of 300 mg/day. This
decision was directed by preliminary data regarding linezolid
in the treatment of MDR-TB in adults being treated with
600 mg/day instead of 1200 mg/day, which is the Food and
Drug Administration-approved dose for Gram-positive organ-
isms [18]. In these studies, a daily 300 mg dose of linezolid
was seen to be effective with less toxicity [19].
Conclusion
Specific strategies and measures should be engaged to pre-
vent the propagation and dissemination of MDR-TB. Concern-
ing MDR-TB treatment, risks and benefits of each medication
should be deemed when tailoring a therapy. In this case, lin-
ezolid was found to be an effective drug available to treat
MDR-TB. Although linezolid was efficacious in this study, ran-
domized clinical trials are necessary to measure outcomes
and permanent side effects of linezolid-containing regimens
before the clinical role of linezolid as a treatment for MDR-
TB can be recommended.
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